Staples E R, McDermott E M, Reiman A, Byrd P J, Ritchie S, Taylor A M R, Davies E G
Department of Immunology, Queen's Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK.
Clin Exp Immunol. 2008 Aug;153(2):214-20. doi: 10.1111/j.1365-2249.2008.03684.x. Epub 2008 May 26.
Immunodeficiency affects over half of all patients with ataxia telangiectasia (A-T) and when present can contribute significantly to morbidity and mortality. A retrospective review of clinical history, immunological findings, ataxia telangiectasia mutated (ATM) enzyme activity and ATM mutation type was conducted on 80 consecutive patients attending the National Clinic for Ataxia Telangiectasia, Nottingham, UK between 1994 and 2006. The aim was to characterize the immunodeficiency in A-T and determine its relationship to the ATM mutations present. Sixty-one patients had mutations resulting in complete loss of ATM kinase activity (group A) and 19 patients had leaky splice or missense mutations resulting in residual kinase activity (group B). There was a significantly higher proportion of patients with recurrent sinopulmonary infections in group A compared with group B (31 of 61 versus four of 19 P = 0.03) and a greater need for prophylactic antibiotics (30 of 61 versus one of 19 P = 0.001). Comparing group A with group B patients, 25 of 46 had undetectable/low immunoglobulin A (IgA) levels compared with none of 19; T cell lymphopenia was found in 28 of 56 compared with one of 18 and B cell lymphopenia in 35 of 55 compared with four of 18 patients (P = 0.00004, 0.001 and 0.003 respectively). Low IgG2 subclass levels and low levels of antibodies to pneumococcal polysaccharide were more common in group A than group B (16 of 27 versus one of 11 P = 0.01; 34/43 versus six of 17 P = 0.002) patients. Ig replacement therapy was required in 10 (12.5%) of the whole cohort, all in group A. In conclusion, A-T patients with no ATM kinase activity had a markedly more severe immunological phenotype than those expressing low levels of ATM activity.
免疫缺陷影响超过半数的共济失调毛细血管扩张症(A-T)患者,一旦出现,会显著增加发病率和死亡率。对1994年至2006年间在英国诺丁汉国家共济失调毛细血管扩张症诊所就诊的80例连续患者进行了临床病史、免疫学检查结果、共济失调毛细血管扩张症突变(ATM)酶活性及ATM突变类型的回顾性研究。目的是明确A-T患者的免疫缺陷特征,并确定其与所存在的ATM突变的关系。61例患者的突变导致ATM激酶活性完全丧失(A组),19例患者有拼接缺陷或错义突变导致残余激酶活性(B组)。A组反复发生鼻窦肺部感染的患者比例显著高于B组(61例中的31例对19例中的4例,P = 0.03),且更需要预防性使用抗生素(61例中的30例对19例中的1例,P = 0.001)。比较A组和B组患者,46例中的25例免疫球蛋白A(IgA)水平检测不到/较低,而19例中无一例如此;56例中的28例发现T细胞淋巴细胞减少,而18例中的1例如此,55例中的35例发现B细胞淋巴细胞减少,而18例中的4例如此(P分别为0.00004、0.001和0.003)。A组中低IgG2亚类水平和肺炎球菌多糖抗体水平低的情况比B组更常见(27例中的16例对11例中的1例,P = 0.01;43例中的34例对17例中的6例,P = 0.002)。整个队列中有10例(12.5%)需要进行Ig替代治疗,均在A组。总之,无ATM激酶活性的A-T患者的免疫表型明显比表达低水平ATM活性的患者更严重。